Format

Send to

Choose Destination
PLoS One. 2015 Jun 17;10(6):e0128542. doi: 10.1371/journal.pone.0128542. eCollection 2015.

Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib.

Author information

1
Evotec (München) GmbH, Dept. of Bioinformatics, Am Klopferspitz 19a, 82152 Martinsried, Germany.
2
Center for Medical Biotechnology, University of Duisburg-Essen, Universitätsstrasse 1-4, 45141 Essen, Germany.
3
Evotec (München) GmbH, Dept. of Bioinformatics, Am Klopferspitz 19a, 82152 Martinsried, Germany; Max-Plack Institute for Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany.

Abstract

Multivariate biomarkers that can predict the effectiveness of targeted therapy in individual patients are highly desired. Previous biomarker discovery studies have largely focused on the identification of single biomarker signatures, aimed at maximizing prediction accuracy. Here, we present a different approach that identifies multiple biomarkers by simultaneously optimizing their predictive power, number of features, and proximity to the drug target in a protein-protein interaction network. To this end, we incorporated NSGA-II, a fast and elitist multi-objective optimization algorithm that is based on the principle of Pareto optimality, into the biomarker discovery workflow. The method was applied to quantitative phosphoproteome data of 19 non-small cell lung cancer (NSCLC) cell lines from a previous biomarker study. The algorithm successfully identified a total of 77 candidate biomarker signatures predicting response to treatment with dasatinib. Through filtering and similarity clustering, this set was trimmed to four final biomarker signatures, which then were validated on an independent set of breast cancer cell lines. All four candidates reached the same good prediction accuracy (83%) as the originally published biomarker. Although the newly discovered signatures were diverse in their composition and in their size, the central protein of the originally published signature - integrin β4 (ITGB4) - was also present in all four Pareto signatures, confirming its pivotal role in predicting dasatinib response in NSCLC cell lines. In summary, the method presented here allows for a robust and simultaneous identification of multiple multivariate biomarkers that are optimized for prediction performance, size, and relevance.

PMID:
26083411
PMCID:
PMC4470654
DOI:
10.1371/journal.pone.0128542
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center